Cybin Inc. Common Stock (HELP) Stock Price
HELPStock
$13.98+79.63%52W
Market Cap$1.02B
P/E—
PEG Ratio—
Div yield—
Beta0.52
HELP Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)74.47%
Price vs S&P 500 (4W)55.81%
VGM Score89.27
HELP Earnings Surprise History
Q2 25-0.70est. -0.80
Q3 25-1.20est. -0.96
Q4 25-0.98est. -0.70
Q1 26-0.87est. -0.82
Q2 26-0.91est. -1.00
HELP Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
HELPCybin Inc. Common Stock | — | — | A | $13.98 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Cybin Inc. Common Stock
Helus Pharma is a clinical-stage biopharmaceutical company developing serotonergic agonists to treat mental health disorders, including depression and anxiety. The company's lead candidate, HLP003, is in Phase 3 development for adjunctive treatment of major depressive disorder. With operations across North America and Europe, Helus Pharma addresses an underserved market for innovative neuropsychiatric therapies.